Michael Mina, MD, PhD

Michael Mina, MD, PhD, of Invivyd explains how a few amino acid changes let VYD2311 move from IV to a single IM shot that could expand access.

Michael Mina, MD, PhD, explains LIBERTY trial findings on VYD2311 tolerability alone and given with an mRNA COVID-19 vaccine.

Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.

Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.